In ischemic stroke, treatment options are limited. Therapeutic thrombolysis is restricted to the first few hours after stroke, and the utility of current platelet aggregation inhibitors, including GPIIb/IIIa receptor antagonists, and anticoagulants is counterbalanced by the risk of intracerebral bleeding complications. Numerous attempts to establish neuroprotection in ischemic stroke have been unfruitful. Thus, there is strong demand for novel treatment strategies.
IntroductionStroke is the second leading cause of death worldwide. 1,2 Approximately 80% of strokes are caused by focal cerebral ischemia due to arterial occlusion, whereas up to 20% are caused by intracerebral hemorrhages. 3,4 Extracranial artery stenoses are prone to destabilization and plaque rupture leading to cerebral thromboembolism. 5 In approximately one-third of ischemic stroke patients, embolism to the brain originates from the heart, especially in atrial fibrillation. 6 Thromboembolic occlusion of major or multiple smaller intracerebral arteries leads to focal impairment of the downstream blood flow, and to secondary thrombus formation within the cerebral microvasculature.In the center of the ischemic territory, oxygen and glucose deprivation, neuronal depolarization, and Ca 2ϩ -mediated excitotoxicity induce necrotic and apoptotic cell death. In the penumbra region surrounding the infarct core, however, tissue is preserved for a certain time span depending on whether blood flow is restored. 7 Since numerous agents that proved neuroprotective in experimental stroke failed in subsequent clinical trials, 8 the only effective treatment option in acute ischemic stroke remains immediate thrombolysis. In this review, we will focus on the initiating event of stroke development, namely intravascular thrombus formation, and highlight promising novel molecular targets for its prevention and treatment.
Current treatment options in ischemic stroke
Thrombolytic therapyIn acute thromboembolic stroke the principal treatment goal is to rapidly achieve recanalization of occluded intracerebral vessels. In the case of a permanent vessel occlusion, a complete infarct will inevitably develop. At present, early intravenous or intra-arterial thrombolysis are the only established therapeutic options. 9,10 Less than 10% of patients are amenable to this treatment due to the limited time window of up to 3 to 6 hours after symptom onset because of the risk of severe intracerebral hemorrhage with later application. 11 A trial to extend the therapeutic window up to 9 hours by use of recombinant desmoteplase, a novel plasminogen activator, failed. 12 For unknown reasons, thrombolytic treatment leads to the dissolution of the vessel-occluding clots in some cases, but not in others. Moreover, secondary arterial reocclusion may follow a previously successful recanalization. 13 Most importantly, patients may develop progressive stroke despite sustained early reperfusion of previously occluded major intracranial arteries, a process referred to as "reperfusion injury." Thes...